Patients characteristics
| Characteristics . | N = 28 . | |
|---|---|---|
| Male | 17 | (60.7%) |
| Age at PID diagnosis (y) | 30 | (14-68) |
| Age at ITP diagnosis (y) | 31 | (5-68) |
| Follow-up duration after ITP diagnosis (mo) | 81 | (11-324) |
| Type of PID | ||
| CVID | 24 | (85.7%) |
| Including LOCID | 3 | (10.7%) |
| HIGM | 1 | (3.6%) |
| CTLA4 deficiency | 1 | (3.6%) |
| PI3KCD mutation | 1 | (3.6%) |
| KMT2D mutation (Kabuki syndrome) | 1 | (3.6%) |
| Immunoglobulin serum levels at the time of PID diagnosis (mg/dL) | ||
| IgG | 326 | (85-486) |
| IgA | 27 | (0-146) |
| IgM | 39 | (4-500) |
| Characteristics . | N = 28 . | |
|---|---|---|
| Male | 17 | (60.7%) |
| Age at PID diagnosis (y) | 30 | (14-68) |
| Age at ITP diagnosis (y) | 31 | (5-68) |
| Follow-up duration after ITP diagnosis (mo) | 81 | (11-324) |
| Type of PID | ||
| CVID | 24 | (85.7%) |
| Including LOCID | 3 | (10.7%) |
| HIGM | 1 | (3.6%) |
| CTLA4 deficiency | 1 | (3.6%) |
| PI3KCD mutation | 1 | (3.6%) |
| KMT2D mutation (Kabuki syndrome) | 1 | (3.6%) |
| Immunoglobulin serum levels at the time of PID diagnosis (mg/dL) | ||
| IgG | 326 | (85-486) |
| IgA | 27 | (0-146) |
| IgM | 39 | (4-500) |
Normal values (ranges): IgG, 650 to 1400 mg/dL; IgA, 70 to 320 mg/dL; IgM, 50 to 350 mg/dL. Quantitative variables are presented as median (range, minimum to maximum) and qualitative variables as frequency (percentage).
HIGM, hyper IgM syndrome; LOCID, late-onset combined immune deficiency.